Summary
GBI Research, has
released its latest pharma report, "Acute Myeloid Leukemia Therapeutics
Market to 2020 - Novel Therapies to Offer Clinical Benefit in Small Patient
Cohorts"
Treatment and prognosis
in AML is strongly influenced by a patient's age, and their cytogenetic
profile. In the majority of cases these two prognostic influences are linked,
with a higher frequency of unfavorable cytogenetic abnormalities observed in
the elderly. Survival in this cohort of elderly patients is very poor, with a
five year overall survival of 3-8% (Luger, 2010). Despite a relatively advanced
understanding of genetic abnormalities associated with AML, the introduction of
targeted therapies is lagging in this indication in comparison to other cancers
such as breast and lung cancer, with no approved targeted therapies. Such slow
development may be a reflection of AMLs status as an orphan indication.
Click for report details:
http://www.radiantinsights.com/research/acute-myeloid-leukemia-therapeutics-market-to-2020-novel-therapies-to-offer-clinical-benefit-in-small-patient-cohorts
Intensive treatment in
eligible patients (younger patients, and approximately 50% of diagnosed elderly
patients) is typically the combination of the two chemotherapeutic agents
cytarabine and daunorubicin, both of which were approved in the 1960s. In
patients ineligible for intensive first-line chemotherapy, options are very
poor, with the more recently approved Vidaza and Dacogen as the treatment
options, which both offer unsatisfactory survival. Across all newly diagnosed
patients that obtain complete remission, a stem cell transplant offers the highest
chance of long-term survival. However, this procedure is risky, with a higher
rate of treatment related mortality in the absence of better techniques to
reduce the risk of graft-versus-host disease.
The majority of patients
experience disease relapse, which is almost always fatal. Treatment options in
these patients typically involve the off-label use of chemotherapeutic agents,
whether in combination or as monotherapies.
About Radiant Insights
Radiant Insights is a platform for companies looking to meet
their market research and business intelligence requirements. We assist and
facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment